The IQSEC1 Knockout HT29 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the IQSEC1 gene in the HT29 human colorectal adenocarcinoma cell line. This loss-of-function model is designed for researchers investigating the molecular mechanisms of cancer cell migration, invasion, and metastasis. The polyclonal population consists of a heterogeneous pool of edited cells, allowing for the study of IQSEC1 deficiency without clonal selection artifacts. This format is particularly suitable for pathway analysis and functional genomics studies where gene disruption is achieved across a bulk cell population.
The HT29 cell line was originally isolated from a colon adenocarcinoma of a 44-year-old Caucasian female and serves as a widely used model for colorectal adenocarcinoma. HT29 cells form polarized epithelial monolayers, making them valuable for studying intestinal epithelial barrier function, tight junction integrity, and drug permeability. This cell line retains key signaling pathways relevant to colon cancer progression, including those regulating adhesion, proliferation, and differentiation, providing a physiologically relevant background for investigating IQSEC1 function in colorectal cancer.
IQSEC1 (also known as BRAG2) functions as a guanine nucleotide exchange factor (GEF) for the small GTPase ARF6, catalyzing its activation by GDP/GTP exchange. IQSEC1 activity is regulated by upstream signals from integrin receptors, epidermal growth factor receptor (EGFR), calcium/calmodulin, and various G protein-coupled receptors (GPCRs). Upon activation, the IQSEC1?CARF6 signaling axis promotes phosphoinositide metabolism through PIP5K-mediated PIP2 generation, leading to actin cytoskeleton remodeling and ??1 integrin recycling to the cell surface. This cascade involves key interactors including calmodulin, paxillin, and focal adhesion kinase (FAK), and drives downstream activation of Rac1, collectively enhancing cell adhesion turnover and directional migration.
In the HT29 colorectal cancer context, IQSEC1 knockout provides a powerful tool to dissect its role in integrin-mediated cell adhesion, transendothelial migration, and invasive behavior. Given HT29 cells?? ability to form tumor-like structures and their relevance to colorectal carcinoma, this model enables investigation of how IQSEC1 loss affects metastatic potential, epithelial-mesenchymal transition, and response to chemotherapeutic agents. The knockout cells are expected to exhibit altered ARF6 activation, impaired integrin recycling, and reduced migratory capacity, offering insights into IQSEC1 as a therapeutic target for colorectal cancer metastasis.
This IQSEC1 knockout polyclonal cell pool is suited for a broad range of applications, including cancer metastasis studies, cell adhesion and migration assays, endocytosis research, and validation of anti-metastatic drug candidates. Representative assays include western blotting and RT-qPCR to confirm gene disruption and assess downstream target expression, immunofluorescence to visualize actin cytoskeleton and integrin distribution, Transwell migration/invasion assays to quantify motility changes, and ARF6 activation pull-downs to monitor GTPase activity. Additionally, phospho-signaling analysis and drug sensitivity testing can be performed to evaluate IQSEC1-dependent signaling networks. Researchers employing this model can robustly probe IQSEC1??s mechanistic contributions and therapeutic relevance. For detailed protocols or technical assistance, please contact Ascent Research.
